Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 1/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 8/20 | 0.47 |
| ▸ | SCD5 | Q86SK9 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | IGF1R | P08069 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2809270 | 0.88 | ADAM17 (0.50) | ADAM17ROCK2SCD5HSD17B10 | |
| SCHEMBL28168304 | 0.79 | ROCK2 (0.56) | ADAM17ROCK2SCD5HSD17B10OPRM1 | |
| SCHEMBL2810568 | 0.79 | ROCK2 (0.42) | ADAM17ROCK2SCD5ALDH1A1 | |
| SCHEMBL19151688 | 0.77 | ADAM17 (0.54) | ADAM17ROCK2SCD5HSD17B10OPRM1 | |
| SCHEMBL2809146 | 0.76 | CCNC (0.39) | ADAM17ROCK2SCD5 | |
| SCHEMBL8542566 | 0.74 | ROCK2 (0.62) | ROCK2SCD5HSD17B10ALDH1A1 | |
| SCHEMBL21392838 | 0.74 | ROCK2 (0.52) | ADAM17ROCK2SCD5HSD17B10ALDH1A1 | |
| SCHEMBL9288463 | 0.74 | RIPK1 (0.54) | ADAM17 | |
| SCHEMBL17513404 | 0.73 | ROCK2 (0.70) | ROCK2 | |
| SCHEMBL18510351 | 0.72 | FKBP1A (0.52) | ADAM17ROCK2SCD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120321559-A1 | HEXAHYDRO-PYRROLO-ISOQUINOLINE COMPOUNDS | APODACA RICHARD (US) | 2012-12-20 | — | — | US | disclosed |
| US-8273762-B2 | Hexahydro-pyrrolo-isoquinoline compounds | JANSSEN PHARMACEUTICA NV (BE) | 2012-09-25 | — | — | US | disclosed |
| US-20100240648-A1 | HEXAHYDRO-PYRROLO-ISOQUINOLINE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-23 | — | — | US | disclosed |
| US-7754882-B2 | Hexahydro-pyrrolo-isoquinoline compounds | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-13 | — | — | US | disclosed |
| EP-1893613-A1 | HEXAHYDRO-PYRROLO-ISOQUINOLINE COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006138604-A1 | HEXAHYDRO-PYRROLO-ISOQUINOLINE COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-28 | — | — | WO | disclosed |
| US-20060293316-A1 | HEXAHYDRO-PYRROLO-ISOQUINOLINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293316-A1 | HEXAHYDRO-PYRROLO-ISOQUINOLINE COMPOUNDS | HRH3, HRH1, HRH4 | ADAM17 4741/4885ROCK2 3979/4885SCD5 3809/4885 |
| US-20100240648-A1 | HEXAHYDRO-PYRROLO-ISOQUINOLINE COMPOUNDS | HRH3, HRH1, HRH4 | ADAM17 4741/4885ROCK2 3979/4885SCD5 3809/4885 |
| US-20120321559-A1 | HEXAHYDRO-PYRROLO-ISOQUINOLINE COMPOUNDS | HRH3, HRH1, HRH4 | ADAM17 4741/4885ROCK2 3979/4885SCD5 3809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.